Intervention
Ocrelizumab
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 68 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownNon-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple SclerosisNCT07827586 · 2026-09-30
RECRUITINGA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10
RECRUITINGStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisNCT07389590 · 2026-02-10
RECRUITINGA Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisNCT07321093 · 2025-11-01
RECRUITINGEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.NCT06846281 · 2025-06-23
RECRUITINGAn Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentNCT06675955 · 2024-12-13
RECRUITINGA Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150 · 2024-09-26
RECRUITINGIDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDEDA Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisNCT07483450 · 2025-07-04
ACTIVE_NOT_RECRUITINGEffects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisNCT06495593 · 2025-02-04
ENROLLING_BY_INVITATIONEffect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSNCT05974852 · 2023-10-01
COMPLETEDEffect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)NCT05974839 · 2023-10-01
COMPLETEDA Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisNCT05208840 · 2023-09-15
WITHDRAWNOcrelizumab Discontinuation in Relapsing Multiple SclerosisNCT05285891 · 2023-02-07
ACTIVE_NOT_RECRUITINGExploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfNCT05266469 · 2022-07-26
COMPLETEDA Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)NCT05123703 · 2022-05-19
ACTIVE_NOT_RECRUITINGA Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisNCT05269004 · 2022-05-03
ACTIVE_NOT_RECRUITINGB Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisNCT05296161 · 2022-04-20
ACTIVE_NOT_RECRUITINGA Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During PregnancyNCT04998812 · 2022-04-13
COMPLETEDLONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMABNCT05210621 · 2022-03-08
ACTIVE_NOT_RECRUITINGOcrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.NCT04877457 · 2022-02-15
TERMINATEDOcrelizumab Access by Socio-Economic StatusNCT05131984 · 2021-11-18
COMPLETEDInvestigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MSNCT04874597 · 2021-11-15
UNKNOWNA Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNCT05688436 · 2021-09-24
ACTIVE_NOT_RECRUITINGA Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabNCT04998851 · 2021-09-16
COMPLETEDOcrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialNCT04971005 · 2021-08-27
TERMINATEDTime and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple SclerosisNCT04676555 · 2021-05-11
COMPLETEDNon-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisNCT04688788 · 2021-04-28
ACTIVE_NOT_RECRUITINGEffects of Ocrevus in Relapsing Multiple SclerosisNCT04387734 · 2021-02-05
ACTIVE_NOT_RECRUITINGSafety and Efficacy of Cladribine Therapy After Anti CD20 TherapyNCT04640818 · 2020-12-17
UNKNOWNA Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)NCT04548999 · 2020-12-03
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)NCT04544436 · 2020-11-26
ACTIVE_NOT_RECRUITINGOcrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseNCT04578639 · 2020-11-02
ACTIVE_NOT_RECRUITINGSymptom Burden in Patients Treated With Ocrelizumab for Multiple SclerosisNCT04855617 · 2020-10-26
COMPLETEDA Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisNCT04544449 · 2020-10-26
ACTIVE_NOT_RECRUITINGImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis OnsetNCT04466150 · 2020-08-30
ACTIVE_NOT_RECRUITINGOcrelizumab in BreastmilkNCT04387110 · 2020-08-07
COMPLETEDEffects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple SclerosisNCT04261790 · 2020-08-01
COMPLETEDProspective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabNCT04377555 · 2020-07-30
COMPLETEDMechanistic Study of OcrevusNCT04459988 · 2020-07-01
COMPLETEDA Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisNCT04075266 · 2020-01-09
ACTIVE_NOT_RECRUITINGA Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple SclerosisNCT03972306 · 2019-08-12
COMPLETEDA Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisNCT04035005 · 2019-08-12
ACTIVE_NOT_RECRUITINGOcrelizumab Effects on the Metabolome in MSNCT03873389 · 2019-06-12
COMPLETEDShort-term B-cell Depletion in Relapsing Multiple SclerosisNCT03853746 · 2019-04-01
COMPLETEDReal-world Data of Ocrelizumab in Multiple Sclerosis in LATAMNCT03784547 · 2019-02-01
UNKNOWNNon-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple SclerosisNCT03593590 · 2018-11-12
COMPLETEDEffect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714NCT03691077 · 2018-11-11
UNKNOWNUpper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusNCT03562975 · 2018-07-23
COMPLETEDThis is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)NCT03599245 · 2018-07-12
COMPLETEDA Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisNCT03523858 · 2018-05-28
ACTIVE_NOT_RECRUITINGRandomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)NCT03477500 · 2018-03-21
ACTIVE_NOT_RECRUITINGOcrelizumab Effects on Physiological and Cognitive Changes in Multiple SclerosisNCT03025269 · 2017-11-15
COMPLETEDStudy to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)NCT03085810 · 2017-03-24
TERMINATEDSafety of Switching From Rituximab to Ocrelizumab in MS PatientsNCT02980042 · 2017-01-01
COMPLETEDA Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02861014 · 2016-09-09
COMPLETEDStudy to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)NCT02688985 · 2016-04-29
COMPLETEDA Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02637856 · 2016-02-11
COMPLETEDA Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01412333 · 2011-09-20
COMPLETEDA Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01247324 · 2011-08-31
COMPLETEDCommon conditions
Multiple Sclerosis32Multiple Sclerosis, Relapsing-Remitting7Relapsing Multiple Sclerosis7Primary Progressive Multiple Sclerosis6Rheumatoid Arthritis5Clinically Isolated Syndrome4Multiple Sclerosis, Primary Progressive4Relapsing Remitting Multiple Sclerosis3Relapsing-Remitting Multiple Sclerosis3Autoimmune Diseases2Demyelinating Diseases2Immune System Diseases2Nervous System Diseases2Autoimmune Diseases of the Nervous System1Demyelinating Autoimmune Diseases, Central Nervous System (CNS)1Multiple Sclerosis (MS)1Multiple Sclerosis, Relapsing1Non-Active Secondary Progressive Multiple Sclerosis1Non-Active SPMS1Pathologic Processes1Primary Progressive Multiple Sclerosis (PPMS)1Progressive Multiple Sclerosis1Progressive Multiple Sclerosis (PMS)1Radiologically Isolated Syndrome1Relapse1
Leading sponsors
Hoffmann-La Roche
25
Genentech, Inc.
9
Johns Hopkins University
4
Novartis Pharmaceuticals
3
University of California, San Francisco
3
Haukeland University Hospital
2
State University of New York at Buffalo
2
Amsterdam UMC, location VUmc
1
Assistance Publique - Hôpitaux de Paris
1
Biocad
1
Biogen
1
Brigham and Women's Hospital
1
Centre Hospitalier Universitaire de Nice
1
Claudio Gobbi
1
Copenhagen University Hospital, Rigshospitalet
1
Trial status mix
COMPLETED27
ACTIVE_NOT_RECRUITING18
TERMINATED8
RECRUITING7
UNKNOWN4
ENROLLING_BY_INVITATION1
NO_LONGER_AVAILABLE1
SUSPENDED1
WITHDRAWN1
Phase mix
PHASE327
PHASE414
PHASE26
PHASE13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.